Patients' use of generative AI (GenAI) independently from healthcare is increasing across diseases. Little is known about its use among people with Parkinson's disease (PwP). This exploratory convenience-sample, mixed-methods online survey (n = 149, 19 countries) explored PwP's use of GenAI. Among our respondents, 65% had used GenAI, of which 40% had used it for disease-specific inquiries. Qualitative analysis identified informational, interpretive, and preparational uses of GenAI. As PwP increasingly bring AI-assisted data to consultations, clinicians must now actively engage in discussions about these tools, to support shared decision-making, safety and transparency.